Drugs / Neosaxitoxin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03399435 | Jan → Sep 2018 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT01786655 | May 2013 → Mar 2014 | — | Charles Berde | Completed | No outcome recorded |
| Phase 1 | NCT00273065 | May → Sep 2005 | — | University of Chile | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neosaxitoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00273065 ↗ |
| Known as | NeoSTX | “Neosaxitoxin (NeoSTX) Alone and in Combination With Bupivacaine as Prolonged Duration Local Anesthetics: A Phase I Investigator-initiated Dose Escalation Study” NCT01786655 ↗ |
| Action | Inhibit | “reversible block the voltage-gated sodium channels at neuronal level” NCT00273065 ↗ |
| Modality | Small molecule | — CHEMBL4297307 ↗ |
| Route | Subcutaneous | “Subcutaneous injections were made in the middle posterior skin of the calf” PMID 17264729 ↗ Feb 2007 |